Search results
Results From The WOW.Com Content Network
Interleukin 6 (IL6) is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in immune response. Dysregulated production of IL6 and this receptor are implicated in the pathogenesis of many diseases, such as multiple myeloma , autoimmune diseases and prostate cancer .
Interleukin 6 (IL-6) is an interleukin that acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine. In humans, it is encoded by the IL6 gene. [5] In addition, osteoblasts secrete IL-6 to stimulate osteoclast formation. Smooth muscle cells in the tunica media of many blood vessels also produce IL-6 as a pro-inflammatory cytokine.
Hyper-IL-6 is a designer cytokine, which was generated by the German biochemist Stefan Rose-John. [1] Hyper-IL-6 is a fusion protein of the four-helical cytokine Interleukin-6 and the soluble Interleukin-6 receptor which are covalently linked by a flexible peptide linker. [1]
IL-6 had previously been classified as a proinflammatory cytokine. Therefore, it was first thought that the exercise-induced IL-6 response was related to muscle damage. [ 22 ] However, it has become evident that eccentric exercises are not associated with a larger increase in plasma IL-6 than exercise involving concentric “nondamaging ...
Interleukin 6 (IL6), also referred to as B-cell stimulatory factor-2 (BSF-2) and interferon beta-2, is a cytokine involved in a wide variety of biological functions. [20] It plays an essential role in the final differentiation of B cells into immunoglobulin-secreting cells, as well as inducing myeloma/plasmacytoma growth, nerve cell ...
Interleukin-8 receptor, RANTES receptors (CCR1, CCR3, CCR5), MIP-1 receptor, PF4 receptor, M-CSF receptor and NAP-2 receptor belong to GPCR chemokine receptor family. References [ edit ]
IL-2 receptor; Interleukin-3 receptor; Interleukin-4 receptor; Interleukin-5 receptor; Interleukin-6 receptor; Interleukin-7 receptor; Interleukin-7 receptor-α; Interleukin-9 receptor; Interleukin-11 receptor; Interleukin-12 receptor; Interleukin-13 receptor; Interleukin-15 receptor; Interleukin-21 receptor; Interleukin-23 receptor ...
Olokizumab is the first interleukin-6 (IL-6) inhibitor approved for treatment of rheumatoid arthritis which blocks directly cytokine instead of its receptor. [1] Olokizumab specifically binds to IL-6 at Site 3, blocking IL-6 ability to form hexameric complex. [2] Olokizumab was developed by R-Pharm group, and was launched in 2020. [3]